Replimune Group (NASDAQ:REPL) Stock Price Up 7.4%

Replimune Group, Inc. (NASDAQ:REPL) shares rose 7.4% during mid-day trading on Friday . The stock traded as high as $11.21 and last traded at $11.15. Approximately 363,584 shares were traded during trading, a decline of 68% from the average daily volume of 1,126,441 shares. The stock had previously closed at $10.38.

Analyst Upgrades and Downgrades

REPL has been the topic of several recent analyst reports. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. decreased their price target on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Barclays raised their price target on shares of Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Finally, Wedbush reissued an “outperform” rating and issued a $16.00 price target on shares of Replimune Group in a research note on Thursday, June 6th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $16.20.

Replimune Group Trading Up 7.2 %

The stock has a market capitalization of $683.55 million, a price-to-earnings ratio of -3.20 and a beta of 1.22. The company’s 50-day moving average is $10.05 and its 200-day moving average is $8.34. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.10. Research analysts anticipate that Replimune Group, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Nisa Investment Advisors LLC increased its position in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Replimune Group in the second quarter valued at approximately $57,000. Quest Partners LLC purchased a new position in shares of Replimune Group in the fourth quarter valued at approximately $76,000. Diversified Trust Co purchased a new position in shares of Replimune Group in the first quarter valued at approximately $94,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after purchasing an additional 4,975 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.